Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Public Storage (PSA) Price & Performance

Bio-Rad Laboratories, Inc. Class A Common StockTrade
Public StorageTrade

Price performance (Past 24H)

Key statistics

Bio-Rad Laboratories, Inc. Class A Common Stock vs Public Storage — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Public Storage trades at $324.41 (market cap $60.82B). The key difference: Public Storage is far larger — about 6.5× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Public Storage pays a 3.68% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.

BIOPSA
Market Cap
$9.39B$60.82B
Sector
HealthReal Estate
52-Week High
$354.54$330.47
52-Week Low
$241.71$258.44
Enterprise Value
$9.14B$75.10B
Dividend Yield
3.68%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bio-Rad Laboratories, Inc. Class A Common Stock

BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.

The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.

Public Storage

Public Storage (PSA) trades at $328.40, up 0.43% on the day, with a bullish technical signal from moving averages and a consensus price target of $333.88. The company reported Q2 2026 EPS of $2.55, beating estimates, and raised full-year guidance following the acquisition of National Storage Affiliates. Strong profitability is evident with a net income margin of 41.8% and ROE of 37.42%, though valuation multiples like P/E of 31.34 suggest a premium.

Outlook remains positive due to accretive acquisitions and dividend stability, with a $3.00 quarterly dividend declared. Risks include high valuation, interest rate sensitivity, and integration challenges from recent deals. Analyst sentiment is mixed with 28.6% buy ratings, but institutional activity shows both position increases and cuts, indicating cautious optimism.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO

About Public Storage

Public Storage is the largest owner of self-storage facilities in the U.S. with more than 2,800 self-storage facilities in 39 states and approximately 200 million square feet of rentable space. Through equity interests, it also has exposure to the European self-storage market through Shurgard Self Storage and to an additional 28 million net rentable square feet of industrial space in the United States through PS Business Parks.

Read more on PSA